LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence ...
BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) ...
Stocktwits on MSN
Genmab stock slips after discontinuing further development of cancer drug developed with BioNTech
The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. Pfizer and ...
People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Investors were cheered ...
BioNTech has posted an early win for BNT111, linking a combination of the cancer immunotherapy candidate and Regeneron’s checkpoint inhibitor Libtayo to a better response rate than a historical ...
BioNTech has added evidence that PD-(L)1xVEGF-A bispecifics can unseat Keytruda. The German biotech reported an 18-month overall survival rate of 69.7% in a phase 1b/2 breast cancer trial, handily ...
Moderna said Friday that it is suing Pfizer and BioNTech, alleging that the two companies copied Moderna's technology to make their Covid vaccine Comirnaty. "We believe that Pfizer and BioNTech ...
Messenger RNA technology leaders Moderna and BioNTech have seen their stocks rally by around 75% and 150% respectively year-to-date driven by strong demand for their Covid-19 shots and also as ...
BioNTech CEO Ugur Sahin is taking a big pay cut in 2021, but his large stake in the German company he co-founded still qualifies him for billionaire status. Sahin received a pay package worth 11.59 ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. BioNTech plans to return nearly €2bn to shareholders through share buybacks and a special dividend following ...
A logo of BioNTech is pictured at the headquarter of biopharmaceutical company BioNTech, one of the laboratories in the race to develop a coronavirus vaccine, in Mainz, western Germany. (Photo by Yann ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results